Terms ending in 2039
Every in-force patent on ModernaTX, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,453,766 | RSV RNA Vaccines In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 11,767,548 | RNA Polymerase Variants In force · Medium confidence | ModernaTX, Inc. | In force | Medium confidence | |
| US 11,801,227 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 12,595,476 | Assembly and Error Reduction of Synthetic Genes from Oligonucleotides In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 11,912,982 | Methods for HPLC Analysis In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 11,866,475 | Modified RNA Encoding VEGF-A Polypeptides, Formulations, and Uses Relating Thereto In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 11,969,506 | Lipid Nanoparticle Formulation In force · High confidence | ModernaTX, Inc. | In force | High confidence | |
| US 11,434,486 | Polynucleotides Containing a Morpholino Linker In force · High confidence | ModernaTX, Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.